Matthew Langer

Cooley advised LIXTE Biotechnology, a clinical-stage pharmaceutical company focused on developing and commercializing new cancer therapies, on its clinical trial agreement with The University of Texas MD Anderson Cancer Center and GSK.

Cooley advised Nutrafol, a leading provider of hair wellness products, on its agreement to sell a majority stake in the company to Unilever. Partner Kevin Cooper led the Cooley team advising Nutrafol on the transaction, and partner Stephane Levy has acted as longtime corporate counsel to the company. Nutrafol is backed by Unilever Ventures and consumer-focused private equity firm L Catterton.

Cooley manages the global patent portfolio of Usher III Initiative, Inc., a research consortium of leading retinal and cochlear specialists established to develop treatments for Usher Syndrome Type III.  Usher Syndrome is a genetic disorder that causes progressive hearing and vision loss and affects less than 0.01% of the population worldwide. Cooley’s work has resulted in the issuance of US and foreign patents covering small-molecule therapeutics showing promise as drugs useful for treating Usher Syndrome Type III.